908 Devices Inc.
NASDAQ:MASS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
908 Devices Inc.
908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. The company is headquartered in Boston, Massachusetts and currently employs 177 full-time employees. The company went IPO on 2020-12-18. The firm's Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide answers to address problems in life sciences research, bioprocessing, industrial biotechnology, forensics and adjacent markets. Its products include MX908, Rebel and ZipChip. MX908 is a handheld Mass Spec device designed for analysis of gas, liquid and solid materials of unknown identity. MX908 is a multi-purpose device utilized by a spectrum of user segments for a variety of forensic field applications, including chemical, explosive, priority drug and hazardous materials operations, detecting materials at the trace level. The Rebel is a desktop analyzer providing real-time information on the extracellular environment in bioprocesses. ZipChip is a plug-and-play separation platform that optimizes Mass Spec sample analysis.
908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. The company is headquartered in Boston, Massachusetts and currently employs 177 full-time employees. The company went IPO on 2020-12-18. The firm's Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide answers to address problems in life sciences research, bioprocessing, industrial biotechnology, forensics and adjacent markets. Its products include MX908, Rebel and ZipChip. MX908 is a handheld Mass Spec device designed for analysis of gas, liquid and solid materials of unknown identity. MX908 is a multi-purpose device utilized by a spectrum of user segments for a variety of forensic field applications, including chemical, explosive, priority drug and hazardous materials operations, detecting materials at the trace level. The Rebel is a desktop analyzer providing real-time information on the extracellular environment in bioprocesses. ZipChip is a plug-and-play separation platform that optimizes Mass Spec sample analysis.
Revenue: Q3 revenue was $14 million, down 4% year-over-year but up 8% sequentially. Year-to-date revenue grew 16% versus last year.
Profitability: Adjusted EBITDA loss improved to $1.8 million, the lowest in company history, and management expects to achieve positive adjusted EBITDA in Q4.
Guidance: Full-year 2025 revenue guidance of $54–56 million was reaffirmed, representing 13–17% growth, despite up to $4 million of Q4 revenue at risk from government delays.
Product Momentum: Strong demand for XplorIR (record Q3 shipments, up 30% QoQ) and early traction for the new Viper analyzer (35+ units booked for Q4).
Cost Improvements: Facility consolidation and insourcing have reduced costs, improved gross margin, and created a more scalable operation.
Government Headwinds: U.S. government shutdown has delayed some large federal orders, but management sees this as a timing issue, not lost business.
